-53%

est. 2Y upside i

HealthcareSeries D+

Truepill is the leading telehealth fulfillment and patient engagement platform.

Rank

#3289

Sector

Health Care Technology

Est. Liquidity

~5Y

Data Quality

Data: Low

Truepill's current valuation of $525M reflects a significant decline from its peak, and the company faces high competitive and regulatory risks.

Last updated: July 21, 2026

Bull (10%)+8%

Multiple expands to 6x due to successful integration with LetsGetChecked and potential IPO, yielding 8.3% upside from entry valuation of $525M.

Base (45%)-19%

Multiple converges to 4.5x, near the middle of comp range, leading to 18.7% decline in valuation.

Bear (45%)-100%

Multiple compresses to 3x or lower due to intense competition from Amazon Pharmacy and regulatory risks, resulting in exit value below $322M preference stack, wiping out common equity.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

6133%

Total funding of $322M represents 61% of the $525M entry valuation, giving preferred holders a large liquidation preference that severely dilutes common equity.

Dilution Risk

low

No additional dilution expected as company is now part of a private parent.

Secondary Liquidity

none

No secondary market exists as the company is privately held and recently acquired.

Questions to Ask at the Interview

Strategic questions based on Truepill's data — designed to show you've done your homework.

  • 1

    “How does Truepill's API-driven model differentiate from Amazon Pharmacy's direct-to-consumer approach?”

  • 2

    “What is the revenue growth trajectory expected from the partnership with LetsGetChecked?”

  • 3

    “How would you assess the risk of further dilution if the parent company needs additional capital?”

Community

Valuation Sentiment

Our model estimates -53% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.